- Nachrichtendetail
-
18.04.2024 15:10:28 - dpa-AFX: AbbVie's Phase 3 Study Of Upadacitinib Achieves Primary Endpoint In Giant Cell Arteritis
WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV) Thursday announced positive
results from SELECT-GCA Phase 3 of Upadacitinib 15 mg, once daily in combination
with a 26-week steroid taper regimen in adults with giant cell arteritis.
The pharma company said its randomized, double-blind, placebo-controlled study
achieved primary endpoint of sustained remission.
The study results showed that 46 percent of patients receiving Upadacitinib 15
mg in combination, achieved sustained remission compared to 29 percent of
patients receiving placebo.
Giant cell arteritis, also known as temporal arteritis, is an autoimmune disease
that causes inflammation of the temporal and other cranial arteries, the aorta,
and other large and medium arteries.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
results from SELECT-GCA Phase 3 of Upadacitinib 15 mg, once daily in combination
with a 26-week steroid taper regimen in adults with giant cell arteritis.
The pharma company said its randomized, double-blind, placebo-controlled study
achieved primary endpoint of sustained remission.
The study results showed that 46 percent of patients receiving Upadacitinib 15
mg in combination, achieved sustained remission compared to 29 percent of
patients receiving placebo.
Giant cell arteritis, also known as temporal arteritis, is an autoimmune disease
that causes inflammation of the temporal and other cranial arteries, the aorta,
and other large and medium arteries.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
ABBVIE INC. DL-,01 | A1J84E | Frankfurt | 160,920 | 18.06.24 16:37:01 | +2,820 | +1,78% | 0,000 | 0,000 | 158,000 | 158,100 |
